A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Lin, Ren-Jang, Ph.D. Research

Ren-Jang Lin, Ph.D. Research
RNA Splicing
Non-coding intervening sequences, or introns, interrupt most eukaryotic genes. Cells must remove introns with great precision from these gene transcripts in order to accurately express the genetic information. Intron removal is done through a process called RNA splicing, and the spliceosome is a ribonucleoprotein complex that splices pre-mRNAs through two transesterification reactions. In addition to being highly precise, the spliceosome is also quite flexible; it can splice different sets of expressing sequences, or exons, together to produce multiple splice variants from one gene transcript. Alternative splicing allows human cells to produce a million of proteins from their 50,000 genes. Thus, an abnormal or defective spliceosome would bring disease or even death to an organism. Our goals are to understand the molecular detail of the spliceosome in model organisms as well as to study its function and regulation in normal and cancerous cells.
 

Human DHX16/PRP2 protein in splicing and cell death

Human DHX16/PRP2 protein in splicing and cell death
Spliceosome requires different DExD/H-box RNA helicases at assembly, activation, and disassembly steps. Mutations in these helicase genes of S. cerevisiae could abolish splicing and cell growth; however, their effect in humans is less known. S. cerevisiae Prp2 protein is a late spliceosomal helicase; prp2 mutants accumulate unspliced pre-mRNA in vivo and their extracts form an inactive pre-catalytic spliceosome in vitro (see project 2). We showed that an siRNA-mediated knockdown of human DHX16 gene expression caused a quick and drastic decrease of mRNAs from several intron-containing genes. Overproduction of the protein mutated at its helicase domain had a similar effect. In both cases, the unspliced pre-mRNA from a reporter was detected. Splicing in HeLa extracts was inhibited by an antibody against a Dhx16 peptide; however, spliceosomes were nonetheless formed. Thus, sequence and function similarities indicate that human Dhx16 is likely the orthologue of S. cerevisiae Prp2. Interestingly, the antibody immunoprecipitated from splicing reactions the spliceosomal snRNAs, unspliced pre-mRNA, and the splicing intermediates. Yeast two-hybrid screens revealed an interaction between hPrp2 and a second-step splicing factor further suggesting a potential role of hPrp2 in spliceosome transition. We have established a stable cell line having a controllable dominant negative hPRP2; upon induction, DNA fragmentation occurred and cells died of apoptosis. This provides an opportunity to examine how splicing, transcription, and cell growth respond to a stall of spliceosome in vivo.

Finding alternative splicing variants in breast cancer

Finding alternative splicing variants in breast cancer
Growing evidence indicates that alternative or aberrant pre-mRNA splicing takes place during the development, progression, and metastasis of breast cancer. However, what splicing changes are really important in tumorigenesis and cancer biology remains to be elucidated.
 
We used microarrays of junction oligonucleotides representing 120 alternative exons of 64 genes to detect splicing differences between breast cancer cells and normal human mammary epithelial cells. Several splicing alterations in genes including CD44, FAS, APLP2 and MYL6 were detected by microarrays and RT-PCR.
We also compared two breast cancer cell lines MCF7 (estrogen receptor positive) and MDA-MB-231 (estrogen receptor negative) cultured in two-dimensional (2D) flat dish or in three-dimensional (3D) Matrigel. Interestingly, only a subset of the splicing alterations between MCF7 and MDA-MB-231 cells detected in 2D samples was retained in 3D samples, suggesting culturing conditions affect splicing variations.
 
We further compared splicing in MCF7 cells grown in dish, Matrigel, or xenograft in mouse and found at least one example that splicing variants expressed in xenograft could be identified in 3D but not in 2D cultures. Thus, our preliminary investigation indicates that microarrays can be used to identify splicing variants that potentially can be used as breast cancer markers.
 

The catalytic core of the spliceosome

The catalytic core of the spliceosome
The spliceosome is composed of five small nuclear RNAs and about a hundred of proteins, whose function is to recognize and splice exons together. A longstanding question about spliceosome function is whether snRNAs or proteins catalyze the splicing reaction. Since the spliceosome is a metalloenzyme, finding the spliceosomal components that coordinate catalytic metals is crucial in addressing the question. There is evidence of genetic and biochemical nature indicating that the U6 snRNA is at the catalytic core of the spliceosome.
 
By reconstituting the yeast spliceosome with a phosphorothioate-substituted U6 snRNA, we demonstrated that the 5’ phosphate of the eightieth nucleotide (U80) of U6 coordinates a catalytically important magnesium ion for the first step of splicing. We found, using similar approaches, that phosphates of A59 and G60 of U6 snRNA are also critical for the catalytic activity of the spliceosome. Thus, these observations support the idea that U6 snRNA is not only at the core of the spliceosome but also directly participates in the chemical reaction of splicing, and that the spliceosome may have a evolutionary root in RNA-based machinery.
 

Yeast splicing extracts preparation

Protocol 1: Yeast splicing extracts preparation
Extract preparation for in vitro pre-mRNA splicing. YPD cultures of S. cerevisiae mutant strain 3.2 A1D [MATa, prp2-1, ade2, his3, lys2-801, ura, first described in 19991] were grown at 26°C until they reached late logarithmic phase (A600 of 3-5). 2 mls of the protease inhibitor phenylmethyl sulfonyl fluoride [0.5M PMSF] per liter of culture were added and the culture was allowed to grow for another 30 min.
 
Cells were collected by centrifugation at room temperature for 10 min at 7000 (3800 x g) in a Sorvall GS3 rotor. The wet weight of the cells (30g) were measured and this value was used for the rest of the extract preparation procedure. Pellets were re-suspended in 150mls of TE Buffer [50mM Tris-HCl (pH 8.0), 0.2mM EDTA (pH 8.0)] at 50mls per 10g of cells.
 
Cells were collected by centrifugation at room temperature for 6 min at 6000 (2800 x g) in a GS3 rotor. Pellets were then re-suspended in 90mls of SB30 buffer [1M Sorbitol, 50mM Tris-HCl (pH 7.8), 10mM MgCl2, 30mM DTT] at 30 mls per 10g of cells. Cells were collected by centrifugation at room temperature for 6 min at 6000 rpm (3900 x g) in a Sorvall GSA rotor. Pellets were next re-suspended in 60mls of SB3 buffer [1M Sorbitol, 50mM Tris-HCl (pH 7.8), 10mM MgCl2, 3mM DTT] at 20mls per 10g of cells. 10ul of suspended cells were added to 1ml of 10% SDS and the A800 was measured.
 
The suspended cells were treated with the supernatant from the addition of 9 mg of zymolyase (from ICN, TM-100T)in 600ul of zymolyase buffer [20mM KPO4 (pH 7.8), 5% glucose] at 3 mg and 200ul per 10g of cells, respectively. The cells were shaken at 30°C for 75 min at 120 rpm and then the A800 was re-measured by adding 10ul of the zymolyase-treated cell suspension plus 1ml of 10% SDS. Before proceeding, the A800 of the suspension must decrease by >80% from the initial absorbance reading.
 
Zymolyase (from Seikagaku) treated cells, called spheroblasts, were collected by centrifugation at room temperature for 5 min at 3000 rpm in a GSA rotor. The pellets were gently re-suspended in 90mls of SB3 containing 0.5mM PMSF at 30mls per 10g of cells. The spheroblasts were collected at room temperature for 5 min at 3000 rpm in a GSA rotor. Spheroblast pellets were chilled on ice for 30 min.\
 
Pellets were re-suspended in 30mls of buffer A containing protease inhibitors [10mM HEPES (pH 7.8), 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 1uM leupeptin, 1uM pepstatin, 1um benzamdine, 1uM PMSF] at 10mls per 10g of cells. Re-suspended pellets were poured into a dounce glass homogenizer (type B) and lysed by 14 hard strokes [7 up and 7 down], with 2 min between each pair of strokes to allow heat to dissipate.
 
The homogenate volume was measured and transferred to a beaker and 1/10 volume of KCl (0.2M) was added dropwise. The solution was stirred on ice for 30 min and then centrifuged at 4°C for 30 min at 17,000 rpm (22,500 x g) in a Sorvall SS-34 rotor. The supernatant was collected and centrifuged at 4°C for 60 min at 37,000 rpm (140,000 x g) in a Beckman 60Ti rotor. The clear middle layer was collected by a pasteur pipette. The top (lipid-rich) and bottom (cellular debris-rich) layers were discarded. The extract was frozen with liquid N2 and stored at -80°C.
 
The next day the frozen extract was thawed under tap water. The extract was placed in a Spectra/Por 1 dialysis tubing (6000-8000 MWCO) and dialyzed against 1L of buffer D [20mM HEPES (pH 7.8), 20% glycerol, 50mM KCl, 0.2mM EDTA (pH 8), 0.5mM DTT, 0.5mM PMSF] at 4°C, for 3 hrs. The tubing was inverted every 20 min and the buffer was changed after 1 and 2 hrs. The dialyzed mixture was centrifuged at 4°C for 30 min at 17,000 rpm (22,500 x g) in a Sorvall SS-34 rotor. The supernatant was carefully aliquoted into 1.5ml microcentrifuge tubes. The dialyzed extract was frozen in liquid N2 and stored at -80°C
 

Yeast Prp2 ATPase and its associated G-patch protein

Yeast Prp2 ATPase and its associated G-patch protein
One of the major spliceosomal proteins is RNA helicases, whose function is believed to mediate RNA and protein rearrangement in the spliceosome during the splicing cycle. We characterized one such protein called Prp2 in order to elucidate the function of RNA helicases in splicing. We found that yeast spliceosome could recognize the pre-mRNA in the absence of Prp2 but the complex stalled right before the first step of splicing. The block is released and splicing resumed when Prp2 and ATP were provided, indicating that the spliceosome is not active without Prp2 and the activation process requires ATP hydrolysis catalyzed by a spliceosome-bound Prp2. This activation process is likely conserved through evolution since we recently found that human spliceosome also requires a human protein with great similarity to yeast Prp2 for activity (see project 3).
 
There are eight RNA helicases in yeast Saccharomyces cerevisiae that are involved in pre-mRNA splicing and each of them is needed for cell viability. These proteins have highly conserved central helicase domain, which is involved in ATP hydrolysis and is absolutely required for its splicing function. The role of the less conserved amino- and carboxyl-extensions, however, remains unclear. We found that the C-terminal domain of Prp2 and a couple of other spliceosomal helicases is required for spliceosome binding. Moreover, a G-patch protein interacting with Prp2 through the C-domain was identified, and we showed that this interaction is essential for the binding of Prp2 to the spliceosome. This helicase-associated protein called Spp2 is required for yeast splicing and plays a role in providing specificity to Prp2 during spliceosome interaction. It remains to be investigated whether additional helicase-associated proteins are involved in the spliceosome binding of other RNA helicases.
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...
  • Survival rates for childhood cancer have improved tremendously over the past few decades, but postcancer care hasn’t always kept up. More children than ever are now coping with long-term complications and side effects caused by their disease and treatment — one of those being learning difficulties. A new ...
  • When Sheldon Querido, a retired manufacturer’s representative, was diagnosed with bladder cancer, his doctor told him that he’d need to have his bladder removed – and that he’d have to wear an external urine-collection bag for the rest of his life. “My first response was ‘I donR...
  • To stop smoking, two approaches might be better than one. A new study has found that using the medication varenicline, or Chantix – along with nicotine patches – was more effective than the medicine alone in helping people quit. The study, conducted by Stellanbosch University in Cape Town, South Africa, and pub...
  • John Cloer was three months shy of his third birthday in 2004 when he was diagnosed with acute lymphoblastic leukemia. For the next three and a half years, he received chemotherapy at City of Hope, finally obtaining long-term remission. His parents Bill and Gina, along with John and his younger brother Steve, r...
  • News about the risks or benefits of widespread cancer screening seem to arrive daily – 3D mammography for breast cancer, CT scans for lung cancer, PSA tests for prostate cancer and now pelvic exams for some women’s cancers. Missing in the headlines is a reflection of how cancer detection is evolving. Today’s ca...
  • Adults with sickle cell disease soon may have a new treatment option: bone marrow transplants. Children with sickle cell disease have been treated successfully with transplantation of bone marrow, more officially known as hematopoietic stem cells, from other people. But the procedure has been less successful in...